Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
نویسندگان
چکیده
منابع مشابه
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
BACKGROUND Cyclin-dependent kinases (CDKs) regulate cell proliferation and coordinate the cell cycle checkpoint response to DNA damage. Although inhibitors with varying selectivity to specific CDK family members have been developed, selective CDK4/6 inhibitors have emerged as the most attractive antineoplastic agents because of the importance of CDK4/6 activity in regulating cell proliferation ...
متن کاملCyclin Dependent Kinase 9 Inhibitors for Cancer Therapy
Cyclin dependent kinase (CDK) inhibitors have been the topic of intense research for nearly 2 decades due to their widely varied and critical functions within the cell. Recently CDK9 has emerged as a druggable target for the development of cancer therapeutics. CDK9 plays a crucial role in transcription regulation; specifically, CDK9 mediated transcriptional regulation of short-lived antiapoptot...
متن کاملA novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors.
Breast cancer is the most common cancer in women worldwide. Understanding the biology of this tumor is a prerequisite for selecting an appropriate treatment. Cell cycle alterations are seen in many cancers such as breast cancer. Newly popular targeted agent in breast cancer are cyclin dependent kinase inhibitors (CDKIs) which are agents inhibiting the function of cyclin dependent kinases (CDKs)...
متن کاملCyclin-dependent kinase 4/6 inhibition in cancer therapy
3913 Cell Cycle Volume 11 issue 21 Cyclin-dependent kinases (CDKs) drive cell cycle progression and control transcriptional processes. The dysregulation of multiple CDK family members occurs commonly in human cancer; in particular, the cyclin D-CDK4/6-retinoblastoma protein (RB)-iNK4 axis is universally disrupted, facilitating cancer cell proliferation and prompting long-standing interest in ta...
متن کاملCyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.
Cyclin-dependent kinases (CDKs) have been considered promising drug targets for a number of years, but most CDK inhibitors have failed rigorous clinical testing. Recent studies demonstrating clear anticancer efficacy and reduced toxicity of CDK4/6 inhibitors such as palbociclib and multi-CDK inhibitors such as dinaciclib have rejuvenated the field. Favorable results with palbociclib and its rec...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JNCI: Journal of the National Cancer Institute
سال: 2012
ISSN: 1460-2105,0027-8874
DOI: 10.1093/jnci/djs002